J 2017

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

PROCHAZKA, V., T. PAPAJIK, Andrea JANÍKOVÁ, D. BELADA, T. KOZAK et. al.

Basic information

Original name

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

Authors

PROCHAZKA, V., T. PAPAJIK, Andrea JANÍKOVÁ, D. BELADA, T. KOZAK, David ŠÁLEK, A. SYKOROVA, H. MOCIKOVA, V. CAMPR, J. DLOUHA, K. LANGOVA, T. FURST and M. TRNENY

Edition

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2017, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.644

Organization unit

Faculty of Medicine

DOI

UT WoS

000393891300013

Keywords in English

Autologous transplantation; chemotherapy; follicular lymphoma; prognosis

Tags

Tags

International impact, Reviewed
Změněno: 12/4/2018 18:53, Soňa Böhmová

Abstract

V originále

Optimal frontline treatment in younger high tumor-burden risk follicular lymphoma patients remains a challenge given the reduced efficacy of standard immunochemotherapy (R-CHOP) in widespread disease and unclear role of intensive induction. The retrospective non-randomized pair-matched (1: 3) analysis compared 48 intermediate/ high Follicular Lymphoma International Prognostic Index (FLIPI) patients receiving intensive rituximab sequential chemotherapy (R-SQ) with 144 random controls (R-CHOP) matched for age, FLIPI score, and maintenance delivery. Complete response rates were 91.7% and 74.1%, respectively (p = .038). After a median followup of 8.8 (R-SQ) and 6.5 years (R-CHOP), 5-year time to treatment failure, progression-free survival, and overall survival were 80.9%, 83.2%, and 100% and 57.5%, 60.3%, and 92.1% (p = .0044; p = .0047; p = .22), respectively. Intensive treatment was accompanied by higher acute hematologic toxicity and infections, comparable non-hematologic toxicity, and incidence of secondary malignancies. Intensive induction demonstrates superior long-term disease control compared to R-CHOP, with higher acute hematologic toxicity, but without acute treatment-related mortality. Further studies are needed to define ultra-high-risk FL patients benefiting most from treatment intensity.